Toutes les études
Pas encore en recrutementPHASE1, PHASE2INTERVENTIONNEL

Personalized Antisense Oligonucleotide for A Single Participant With PACS1 Gene Mutation Associated With Schuurs-Hoeijmakers Syndrome (SHMS)

This research project is testing a brand-new, carefully made medicine specifically for one individual with a rare condition called Schuurs-Hoeijmakers Syndrome (SHMS). SHMS is caused by a particular change in their PACS1 gene. The medicine is called an 'antisense oligonucleotide' (ASO) and is designed to target this specific genetic change. The study aims to find out if this personalised medicine is safe to use and if it can help improve the person's condition. It's an early-stage study, meaning it's one of the first times this kind of treatment is being tried, and it's custom-built for one patient's exact genetic make-up.

En un coup d'œil

Statut
Pas encore en recrutement
Phase
PHASE1, PHASE2
Sponsor
n-Lorem Foundation
Objectif d'inscription
1
Démarrer
01 Apr 2026
Achèvement estimé
01 Avr 2028

De quoi parle cette étude ?

This study is about a very specific and rare condition called Schuurs-Hoeijmakers Syndrome (SHMS). This syndrome happens because of a particular change, or 'mutation,' in a gene called PACS1. When this gene changes, it doesn't work quite right, which then leads to the symptoms of SHMS.

The researchers are trying a brand-new approach. They have developed a special medicine called an 'antisense oligonucleotide,' or ASO for short. Think of it like a very precise key that can only fit one specific lock – in this case, the specific genetic change in the PACS1 gene that causes SHMS. This particular medicine, called nL-PACS1-001, has been custom-made for just one person, designed to correct the problem caused by their unique gene change.

The main goal of this research is to see if this personalised medicine is safe for the individual and if it can help improve their symptoms or condition. Because this is a very new type of treatment and it's tailored to one person, it's considered an early-stage study (Phase 1 and 2). This means the researchers are carefully checking every step to make sure it's safe before they can consider it for more people in the future.

Points clés

  • This is an early-stage study testing a new, personalised medicine for one person.
  • The medicine is designed to target a specific genetic change causing Schuurs-Hoeijmakers Syndrome (SHMS).
  • The main goals are to check the medicine's safety and see if it helps improve the condition.
  • Participation requires specific genetic confirmation of SHMS and ability to attend appointments.
  • The study involves close monitoring over a period of up to two years.
  • It's a voluntary study, and you can withdraw at any time.

Qui peut être éligible ?

This study is looking for only one participant who meets very specific criteria due to the personalised nature of the treatment.

To be considered, the participant must have Schuurs-Hoeijmakers Syndrome (SHMS) that has been officially confirmed by genetic testing. Specifically, the condition must be caused by a particular change in their PACS1 gene, known as c.607C>T (p.Arg203Trp). The participant's parent(s) or legal guardian must provide their agreement to take part.

It's also important that the participant and their family are able to travel to the study site for appointments and follow-up checks. They must also be able to share their medical records with the study team. People who are currently taking part in another medical study or have been in one within the last three months, or who have any other medical condition that might make it hard to complete the study, would not be able to join this particular research.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Do you have a confirmed diagnosis of Schuurs-Hoeijmakers Syndrome (SHMS)?
  2. Has genetic testing shown your SHMS is caused by the specific PACS1 gene change c.607C>T (p.Arg203Trp)?
  3. Are your parent(s) or legal guardian willing to give consent for you to take part?
  4. Can you travel to the study site for regular appointments?
  5. Are you able to share your medical records with the study team?
  6. Are you currently involved in another clinical trial, or have you been in one in the last three months?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you are eligible and decide to take part, you'll be given the special medicine called nL-PACS1-001. The study team will explain exactly how and when this medicine will be given. You would need to attend regular appointments at the study site so the medical team can closely monitor your health and how the medicine is affecting you. These visits will involve various check-ups and possibly some tests to make sure the medicine is safe and to see if it's helping. The study expects to follow participants for up to 24 months, which is two years, to fully understand the effects of the treatment.

Risques et avantages potentiels

Because this is a very new and personalised medicine, the researchers are carefully looking for potential benefits, such as improvements in the symptoms of SHMS. However, as with any new medicine, there could be unknown side effects or risks. The research team will explain all known potential risks before you decide to take part. It's very important to remember that participating in a study is always voluntary, and you have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Emplacements (1)

  • The Hospital for Sick Children (SickKids)
    Code postal vérifié
    Toronto, Canada

Questions fréquentes

What is Schuurs-Hoeijmakers Syndrome (SHMS)?

SHMS is a rare condition caused by a change in a gene called PACS1, which affects how the body develops and functions.

What is an 'antisense oligonucleotide' (ASO)?

It's a special type of medicine designed to specifically target and correct errors in a person's genes, like a very precise key.

Why is this medicine called 'personalised'?

Because it's custom-made to address the unique genetic change in the PACS1 gene of one specific individual, rather than being a standard medicine for everyone.

Combien de temps durera l'étude ?

The study is planned to follow the participant for up to 24 months, which is two years.

Can anyone with SHMS join this study?

No, this specific study is for one person whose SHMS is caused by a very particular change in the PACS1 gene (c.607C>T (p.Arg203Trp)).

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "Personalized Antisense Oligonucleotide for A Single Particip… vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.